Speed of symptom relief viewed as primary concern for chronic bronchitis patients

Published: 2004-08-06 06:57:00

Updated: 2004-08-06 06:57:00

A recent European six-country survey of 1,100 ACEB (acute exacerbations of chronic bronchitis) patients, conducted by Psyma International Medical Marketing Research and sponsored by Bayer HealthCare, revealed that more than half (55%) wanted an antibiotic that provides faster symptom relief.

T...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK